首页> 外文期刊>Asian Pacific Journal of Cancer Prevention >Improving Participation in Colorectal Cancer Screening: a Randomised Controlled Trial of Sequential Offers of Faecal then Blood Based Non-Invasive Tests
【24h】

Improving Participation in Colorectal Cancer Screening: a Randomised Controlled Trial of Sequential Offers of Faecal then Blood Based Non-Invasive Tests

机译:提高参与结肠直肠癌筛选:随机对照试验的粪便序列的序列优惠基于血液的非侵入性测试

获取原文
           

摘要

Background: Poor participation rates are often observed in colorectal cancer (CRC) screening programs utilising faecal occult blood tests. This may be from dislike of faecal sampling, or having benign bleeding conditions that can interfere with test results. These barriers may be circumvented by offering a blood-based DNA test for screening. The aim was to determine if program participation could be increased by offering a blood test following faecal immunochemical test (FIT) non-participation. Materials and Methods: People were invited into a CRC screening study through their General Practice and randomised into control or intervention (n=600/group). Both groups were mailed a FIT (matching conventional screening programs). Participation was defined as FIT completion within 12wk. Intervention group non-participants were offered a screening blood test (methylated BCAT1/IKZF1). Overall participation was compared between the groups. Results: After 12wk, FIT participation was 82% and 81% in the control and intervention groups. In the intervention 96 FIT nonparticipants were offered the blood test - 22 completed this test and 19 completed the FIT instead. Total screening in the intervention group was greater than the control (88% vs 82%, p0.01). Of 12 invitees who indicated that FIT was inappropriate for them (mainly due to bleeding conditions), 10 completed the blood test (83%). Conclusions: Offering a blood test to FIT non-participants increased overall screening participation compared to a conventional FIT program. Blood test participation was particularly high in invitees who considered FIT to be inappropriate for them. A blood test may be a useful adjunct test within a FIT program.
机译:背景:在结直肠癌(CRC)筛选方案中往往观察到差的参与率,利用粪便潜血试验。这可能来自厌恶粪便采样,或具有可能干扰测试结果的良性出血条件。通过提供基于血液的DNA检验,可以通过提供用于筛选的血液的DNA测试来避难。目的是通过在粪便免疫化学测试(FIT)不参与后提供血液试验来增加方案参与。材料和方法:通过其一般做法邀请人们进行CRC筛查研究,并随机被控制或干预(n = 600 /组)。两组都邮寄了一种合适的(匹配常规筛查计划)。参与定义为12WK内的适合完成。干预组非参与者被提供筛查血液测试(甲基化BCAT1 / IKZF1)。在组之间比较整体参与。结果:12WK之后,控制和干预群体的合适参与为82%和81%。在干预的情况下,96件适合的非唾液化剂被提供血液测试 - 22完成该测试,而19已完成合适。干预组中的总筛选大于对照(88%Vs 82%,P <0.01)。 12个邀请人指示适合的邀请不适合他们(主要是由于出血条件),10种完成了血液检验(83%)。结论:与传统的拟合计划相比,为符合非参与者提供验血以增加整体筛选参与。血液测试参与在被认为适合对他们不适合的邀请人中特别高。血液测试可能是拟合程序中有用的辅助测试。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号